© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A national survey found that primary care physicians had little interest in prescribing buprenorphine or naltrexone.
A systematic review of hep C treatment outcomes in this population shows they have high cure rates and relatively low reinfection rates.
Researchers found critical gaps in the scientific knowledge about the opioid epidemic.
Researchers followed people with a drug-injection history who had been cured of hepatitis C and were receiving addiction treatment.
A literature review shows promising signs that teenagers, like adults, can benefit from methadone, buprenorphine and naltrexone.
A group of experts has issued a call to arms, spotlighting missed opportunities for addiction treatment in hospital settings.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
